| 1 |
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 2023:S0140-6736(23)00061-2. [PMID: 36871574 DOI: 10.1016/S0140-6736(23)00061-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne) 2023;10:1089099. [PMID: 36936239 DOI: 10.3389/fmed.2023.1089099] [Reference Citation Analysis]
|
| 3 |
Castiblanco LL, García de Yébenes MJ, Martín Martín JM, Carmona L. Safety and efficacy in the nursing care of people with rheumatic diseases on janus kinase inhibitor therapy. Rheumatol Int 2022. [PMID: 35982184 DOI: 10.1007/s00296-022-05185-2] [Reference Citation Analysis]
|
| 4 |
Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol 2022;16:737-52. [PMID: 35875997 DOI: 10.1080/17474124.2022.2106216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Aghamohammad S, Sepehr A, Miri ST, Najafi S, Pourshafie MR, Rohani M. Anti‐inflammatory and immunomodulatory effects of Lactobacillus spp. as a preservative and therapeutic agent for IBD control. Immunity Inflam & Disease 2022;10. [DOI: 10.1002/iid3.635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 6 |
Xu Z, Chu M. Advances in Immunosuppressive Agents Based on Signal Pathway. Front Pharmacol 2022;13:917162. [DOI: 10.3389/fphar.2022.917162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Usoltseva OV, Surkov AN, Potapov AS, Movsisyan GB, Chernikov VV. Association of autoimmune hepatobiliary pathology with inflammatory bowel diseases in children. RPJ 2022;25:106-115. [DOI: 10.46563/1560-9561-2022-25-2-106-115] [Reference Citation Analysis]
|
| 8 |
Spiewak TA, Patel A. User's Guide to JAK Inhibitors in Inflammatory Bowel Disease. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Kofla-Dłubacz A, Akutko K, Krzesiek E, Jamer T, Braksator J, Grębska P, Pytrus T, Stawarski A. Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases. J Clin Med 2022;11:994. [PMID: 35207271 DOI: 10.3390/jcm11040994] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Lightner AL, Strong SA. Medical Management of Ulcerative Colitis. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_45] [Reference Citation Analysis]
|
| 11 |
Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: A review. World J Hepatol 2021;13:1956-67. [PMID: 35070000 DOI: 10.4254/wjh.v13.i12.1956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Zöllkau J, Hagenbeck C, Hecher K, Pecks U, Schlembach D, Simon A, Schlösser R, Schleußner E. [Recommendations for SARS-CoV-2/COVID-19 during Pregnancy, Birth and Childbed - Update November 2021 (Long Version)]. Z Geburtshilfe Neonatol 2021. [PMID: 34918334 DOI: 10.1055/a-1688-9398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2022;16:835-44. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 14 |
Borcherding DC, He K, Amin NV, Hirbe AC. TYK2 in Cancer Metastases: Genomic and Proteomic Discovery. Cancers (Basel) 2021;13:4171. [PMID: 34439323 DOI: 10.3390/cancers13164171] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 15 |
Gonciarz M, Pawlak-Buś K, Leszczyński P, Owczarek W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy 2021;13:1135-50. [PMID: 34235974 DOI: 10.2217/imt-2021-0096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Zhang W, Michalowski CB, Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol 2021;9:675194. [PMID: 34150733 DOI: 10.3389/fbioe.2021.675194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 17 |
Verstockt B, Pouillon L, Bossuyt P. Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath. J Crohns Colitis 2021;15:692-3. [PMID: 33104197 DOI: 10.1093/ecco-jcc/jjaa218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
De Lima-Karagiannis A, Juillerat P, Sebastian S, Pedersen N, Bar-Gil Shitrit A, van der Woude CJ. Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. J Crohns Colitis 2020;14:S807-14. [PMID: 33085970 DOI: 10.1093/ecco-jcc/jjaa125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 19 |
Nadpara N, Reichenbach ZW, Ehrlich AC, Friedenberg F. Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications. Dig Dis Sci 2020;65:2769-79. [PMID: 32661765 DOI: 10.1007/s10620-020-06471-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 20 |
D'Amico F, Peyrin-Biroulet L, Danese S. JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. J Crohns Colitis 2020;14:1185-7. [PMID: 32579170 DOI: 10.1093/ecco-jcc/jjaa074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 21 |
Lambin T, Faye AS, Colombel J. Inflammatory Bowel Disease Therapy and Venous Thromboembolism. Curr Treat Options Gastro 2020;18:462-475. [DOI: 10.1007/s11938-020-00304-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 22 |
Roda G, Dal Buono A, Argollo M, Danese S. JAK selectivity: more precision less troubles. Expert Rev Gastroenterol Hepatol 2020;14:789-96. [PMID: 32520647 DOI: 10.1080/17474124.2020.1780120] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 23 |
Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 24 |
Klein M, Núñez P, Bay C, Pizarro C, Sedano R, Quera R. Liver Disorders in Inflammatory Bowel Disease. EMJ Hepatol 2020. [DOI: 10.33590/emjhepatol/20-00040] [Reference Citation Analysis]
|
